Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2021 | 1 |
2022 | 2 |
2023 | 2 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean
charles gauthier
(57 results)?
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study.
Eur J Cancer. 2023 Nov;193:113292. doi: 10.1016/j.ejca.2023.113292. Epub 2023 Aug 18.
Eur J Cancer. 2023.
PMID: 37717282
REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.
Vauchier C, Auclin E, Barthélémy P, Carril-Ajuria L, Ryckewaert T, Borchiellini D, Castel-Ajgal Z, Bennamoun M, Campedel L, Thiery-Vuillemin A, Coquan E, Crouzet L, Berdah JF, Chevreau C, Ratta R, Fléchon A, Lefort F, Albiges L, Gross-Goupil M, Vano YA, Thibault C, Oudard S.
Vauchier C, et al.
J Oncol. 2022 Feb 18;2022:3449660. doi: 10.1155/2022/3449660. eCollection 2022.
J Oncol. 2022.
PMID: 35222642
Free PMC article.
Item in Clipboard
Grade 3-4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study.
Guezour N, Soussi G, Brosseau S, Abbar B, Naltet C, Vauchier C, Poté N, Hachon L, Namour C, Khalil A, Trédaniel J, Zalcman G, Gounant V.
Guezour N, et al. Among authors: vauchier c.
Cancers (Basel). 2022 Aug 11;14(16):3878. doi: 10.3390/cancers14163878.
Cancers (Basel). 2022.
PMID: 36010872
Free PMC article.
Item in Clipboard
Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway.
Vauchier C, Pluvy J, Theou-Anton N, Soussi G, Poté N, Brosseau S, Gounant V, Zalcman G.
Vauchier C, et al.
Lung Cancer. 2021 Oct;160:28-31. doi: 10.1016/j.lungcan.2021.07.016. Epub 2021 Aug 4.
Lung Cancer. 2021.
PMID: 34371300
Item in Clipboard
Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Nuzzo PV, Ravera F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valença LB, Oliveira TM, Vauchier C, Pereira Mestre R, Modesti M, Patrikidou A, Pignata S, Procopio G, Fornarini G, De Giorgi U, Russo A, Francini E.
Nuzzo PV, et al. Among authors: vauchier c.
Ther Adv Med Oncol. 2023 Mar 3;15:17588359231156147. doi: 10.1177/17588359231156147. eCollection 2023.
Ther Adv Med Oncol. 2023.
PMID: 36895852
Free PMC article.
Item in Clipboard
[Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs].
Zaibet S, Vauchier C, Khoudour N, Roulleaux Dugage M, Korb-Savoldelli V, Alexandre J, Blanchet B, Goldwasser F, Thomas-Schoemann A, Bellesoeur A.
Zaibet S, et al. Among authors: vauchier c.
Bull Cancer. 2018 Nov;105(11):1102-1109. doi: 10.1016/j.bulcan.2018.08.005. Epub 2018 Oct 8.
Bull Cancer. 2018.
PMID: 30309623
French.
Item in Clipboard
Cite
Cite